FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with ...

Introduction The U.S. Food and Drug Administration (FDA) has granted approval for Sanofi’s (NASDAQ:SNY) hemophilia therapy, Qfitlia, marking a significant advancement in treatment options for patients ...

The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, introducing a new type of ...

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

In a White House press release Monday, the administration shared with other news sources the same poll results, citing “Trump ties for highest approval he’s ever had — as more Americans say ...

The EMEA s approval permits EVICEL to be marketed ... Safe Harbor Statement This news release contains forward-looking statements. Forward-looking statements provide the Company's current ...

On occasion, also covers American sports, general news and entertainment ... legal loophole that has enabled food companies to bypass approval by the Food and Drug Administration (FDA) when ...

BRIDGEWATER, N.J., March 14, 2025 /PRNewswire/ -- Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the ...

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not ...